Article info

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

Authors

  1. Correspondence to Dr Odette S Reifsnider; odette.reifsnider{at}evidera.com
View Full Text

Citation

Reifsnider OS, Kansal AR, Gandhi PK, et al
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease

Publication history

  • Received February 25, 2020
  • Revised March 11, 2021
  • Accepted April 2, 2021
  • First published May 3, 2021.
Online issue publication 
May 03, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.